Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02913196 · ClinicalTrials.gov registry record · Phase 1

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

A Phase 1 study of Prostate Cancer Metastatic, sponsored by Weill Medical College of Cornell University.

Active
Registry status
Phase 1
Development phase
16
Enrollment target
2
Study locations

NCT02913196: Active Phase 1 study of Prostate Cancer Metastatic, sponsored by Weill Medical College of Cornell University.

NCT02913196 is a Phase 1 study of Prostate Cancer Metastatic that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 16 participants, below the 227-participant average among 17 other Prostate Cancer Metastatic trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02913196, a Phase 1 study of Prostate Cancer Metastatic, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
16 participants
Enrollment target
2
Study locations

Study Summary

This is a multi-center, Phase I study of apalutamide in combination with abiraterone acetate, docetaxel and prednisone in patients with metastatic mastrate resistant prostate cancer (mCRPC). This study is designed to determine the dose that apalutamide can be administered safely in combination with abiraterone acetate, docetaxel and prednisone.

Primary Outcome

Dose limiting toxicities will be measured by using the Common Terminology Criteria for Adverse Events or CTCAE version 4.0 which uses a grading scale from 1-5.

Conditions Studied

Prostate Cancer Metastatic

Interventions

  • DRUG Docetaxel
  • DRUG Apalutamide
  • DRUG Prednisone
  • DRUG Abiraterone acetate

Study Locations (2)

Nebraska

  • GU Research Network/Urology Cancer Center - Omaha

New York

  • Weill Cornell Medical College - New York

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2016-12-30
Est. Completion 2026-10
Phase Phase 1
Weill Medical College of Cornell University

701 total trials

What the registry record for NCT02913196 still lists

NCT02913196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 227-participant average among 17 other Prostate Cancer Metastatic trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Prostate Cancer Metastatic appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.

NCT02913196 reports a single indexed study location in Nebraska, New York.

Frequently Asked Questions

What is clinical trial NCT02913196 about?

NCT02913196 is a clinical study titled "Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC". This is a multi-center, Phase I study of apalutamide in combination with abiraterone acetate, docetaxel and prednisone in patients with metastatic mastrate resistant prostate cancer (mCRPC). This study is designed to determine the dose that apalutamide can be administered safely in combination with...

What is the current status of trial NCT02913196?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-12-30. Estimated completion is 2026-10.

What conditions does trial NCT02913196 study?

This clinical trial studies the following conditions: Prostate Cancer Metastatic.

What interventions are being tested in trial NCT02913196?

The interventions under investigation include: Docetaxel (DRUG), Apalutamide (DRUG), Prednisone (DRUG), Abiraterone acetate (DRUG).

Who is sponsoring clinical trial NCT02913196?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02913196 being conducted?

This trial has 2 study locations across Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer Metastatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02913196's enrollment target sits among peer trials

16 18th of 17 the lowest of 17 other Prostate Cancer Metastatic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02913196, the US trial registry maintained by the National Library of Medicine. NCT02913196 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.